A novel immunoinformatics approach for developing a poly-epitope vaccine targeting foot and mouth disease virus, exploiting structural VP proteins

Bhutta, Muhammad Saad; Awais, Muhammad; Sadaqat, Sahar; Zanchi, Fernando Berton; Shahid, Naila; Qayyum Rao, Abdul

doi:10.1080/07391102.2024.2328735

Journal of Biomolecular Structure and Dynamics

2024

DOI: 10.1080/07391102.2024.2328735

|View full text |Cite

A novel immunoinformatics approach for developing a poly-epitope vaccine targeting foot and mouth disease virus, exploiting structural VP proteins

Muhammad Saad Bhutta,

Muhammad Awais,

Sahar Sadaqat

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Development of recombinant vp1 protein immunised in mice as a model of foot-and-mouth disease vaccine

Widayanti,

Pambudi,

Irawan Setyo Utomo

et al. 2024

BIO Web Conf.

View full text Add to dashboard Cite

Foot-and-mouth disease (FMD) is a highly contagious disease that infects cloven-hoofed animals, becoming a serious threat to livestock production and leading to significant economic losses. The re-occurring FMD outbreak in Indonesia was reported back in 2022, causing hundreds of cattle deaths. The immunogenic viral capsid VP1 protein has been extensively researched as a vaccine candidate despite the fact that the existing FMD vaccine uses an inactivated virus. The vp1 gene (648 bps) from FMD virus serotype O was integrated into pET-32b vector and transformed into Escherichia coli TOP10F’. The recombinant pET32b-VP1-1D plasmid was expressed in E. coli BL21(DE3), followed by N-terminal His tag purification. Protein profiles were determined with SDS-PAGE, showing the target protein at 33KDa. Five 6-week-old BALB/c mice were administered intraperitoneal injections of 50 μg and 100 μg protein, respectively, with two booster shots within two-week intervals. The immune response of polyclonal antibodies was tested using indirect ELISA, resulting in a high absorbance signal compared to non-immunized mice. Thus, the outcomes demonstrate that the VP1 recombinant protein from this study has potential as an immunogen in FMD vaccine development.

show abstract

Development of recombinant vp1 protein immunised in mice as a model of foot-and-mouth disease vaccine

Widayanti,

Pambudi,

Irawan Setyo Utomo

et al. 2024

BIO Web Conf.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

A novel immunoinformatics approach for developing a poly-epitope vaccine targeting foot and mouth disease virus, exploiting structural VP proteins

Cited by 1 publication

References 69 publications

Development of recombinant vp1 protein immunised in mice as a model of foot-and-mouth disease vaccine

Development of recombinant vp1 protein immunised in mice as a model of foot-and-mouth disease vaccine

Contact Info

Product

Resources

About